Conditions: Central Retinal Vein Occlusion
Keywords: CRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 252
Healthy volunteers: no

Brief summary:
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO

Detailed description:

Arms:
arm 1: PRN intravitreal injection arm 2: As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections

Interventions: intervention 1: Sham injection intervention 2: Ranibizumab 0.5 mg
Intervention descriptions: intervention 1: Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle. intervention 2: Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only

Protocol document: